Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 3/20 | 0.65 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.65 |
| ▸ | DRD3 | P35462 | 1/20 | 0.65 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.65 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 15/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13745448 | 0.99 | NR1I2 (0.63) | NR1I2OPRM1DRD3OPRD1HTR2C | |
| SCHEMBL17087224 | 0.82 | NR1I2 (0.45) | NR1I2OPRM1DRD3OPRD1BCHE | |
| SCHEMBL17087299 | 0.79 | NR1I2 (0.43) | NR1I2OPRM1DRD3OPRD1BCHE | |
| Tianeptine SCHEMBL49293 | 0.78 | NR1I2 (1.00) | NR1I2OPRM1DRD3OPRD1HTR2C | |
| Tianeptine SCHEMBL29877330 | 0.78 | NR1I2 (1.00) | NR1I2OPRM1DRD3OPRD1HTR2C | |
| Tianeptine SCHEMBL3996165 | 0.78 | NR1I2 (1.00) | NR1I2OPRM1DRD3OPRD1HTR2C | |
| Tianeptine SCHEMBL29470274 | 0.78 | NR1I2 (1.00) | NR1I2OPRM1DRD3OPRD1HTR2C | |
| Tianeptine SCHEMBL29930593 | 0.78 | NR1I2 (1.00) | NR1I2OPRM1DRD3OPRD1HTR2C | |
| SCHEMBL4255730 | 0.78 | NR1I2 (0.40) | NR1I2OPRM1DRD3OPRD1BCHE | |
| Tianeptine SCHEMBL1231001 | 0.78 | NR1I2 (0.98) | NR1I2OPRM1DRD3OPRD1HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209474-A1 | NOVEL USES FOR DRUGS TARGETING GLUTAMINE SYNTHETASE | NEWTHERA (FR) | 2009-08-20 | — | — | US | disclosed |
| EP-1752143-A1 | Novel uses for drugs targeting glutamine synthetase | NewThera (FR) | 2007-02-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209474-A1 | NOVEL USES FOR DRUGS TARGETING GLUTAMINE SYNTHETASE | GLUL, GLS2, ASNS | NR1I2 516/4885OPRM1 224/4885DRD3 1663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.